| Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2015: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2014: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2013: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Outline of Final Research Achievements |
Patients with HBe antigen negative hepatitis B tend to show severe hepatitis, and thus tend to develop cirrhosis and hepatocellular carcinoma. We analyzed clinical and virological conditions of such patients in this study, and obtained the following three conclusions. The first, ALT abnormality after 2 years of seroconversion (SC) may be evaluated as HBeAg-negative hepatitis. ALT, HBV DNA and HBcrAg levels may be useful in predicting the outcome of patients who showed HBeAg SC. The second, there is an opposite association of the pre-core mutation with viral load before and after HBeAg seroconversion in patients with HBV infection. The third, WFA+-M2BP level is useful to predict levels of hepatic fibrosis and risks of hepatocarcinogenesis. Those results may be beneficial to improve prognosis of patients with HBe antigen negative hepatitis B.
|
